Related Experiment Video

Updated: Jul 15, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Proteomic co-expression of cyclin-dependent kinases 1 and 4 in human cancer cells

Laurence Seabra1, Hilmar Warenius

  • 1Apoptosis Research Group, Life Sciences, Keele University, Keele, Staffordshire, UK.

European Journal of Cancer (Oxford, England : 1990)
|May 8, 2007
PubMed

Insights

Cyclin-dependent kinases (CDKs) like Cdk4 are crucial for cancer growth. Researchers found a unique Cdk1/Cdk4 expression ratio in human cancers, suggesting a new therapeutic target.

Area of Science:

  • Cell biology
  • Molecular oncology
  • Cancer research

Background:

  • Cyclin-dependent kinases (CDKs) regulate cell cycle progression.
  • CDK4 is essential for cancer cell proliferation, while its role in normal cells is being re-evaluated.
  • CDK1 and CDK4 are key regulators of DNA synthesis and cell cycle control.

Purpose of the Study:

  • To investigate the relationship between Cdk1 and Cdk4 proteomic expression in human cancer cell lines and melanoma.
  • To compare Cdk1/Cdk4 expression patterns in cancer cells versus normal cells.
  • To identify potential novel anticancer therapeutic targets based on CDK expression.

Main Methods:

  • Proteomic analysis of Cdk1 and Cdk4 expression in human cancer cell lines.
  • Analysis of clinical data from malignant melanoma patients.
  • Comparison of Cdk1/Cdk4 ratios in cancer cells and normal diploid keratinocytes/fibroblasts.

Main Results:

  • A unique relationship between Cdk1 and Cdk4 proteomic expression was identified in human cancer cell lines.
  • This specific Cdk1/Cdk4 expression pattern was absent in normal diploid keratinocytes and fibroblasts.
  • Human cancer cells exhibited a tighter spread of Cdk1/Cdk4 ratios compared to normal cells.

Conclusions:

  • The distinct Cdk1/Cdk4 expression ratio in cancer cells may confer a selective growth advantage.
  • This finding suggests that the Cdk1/Cdk4 ratio represents a potential novel therapeutic target for anticancer strategies.
  • Targeting the Cdk1/Cdk4 pathway could offer a new approach to treating cancers, including malignant melanoma.

More Related Videos

Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death13:54

Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death

Published on: October 21, 2012

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...